6533b82bfe1ef96bd128d6d7

RESEARCH PRODUCT

Methotrexate as a treatment in ocular cicatricial moderate pemphigoid.

Manuel Díaz-llopisE. España GregoriE. Jiménez HerreroA. Hervás OntiverosD. Salom

subject

Pemphigoidmedicine.medical_specialtyPhotophobiaEtiologyMetotrexatePemphigoid Benign Mucous MembraneComplications scarHyperemiaBasement MembraneDiagnosis ocular cicatricial pemphigoidmedicineUso terapeuticoHumansOcular cicatricial pemphigoidAgedBasement membraneKeratitisbusiness.industrySymblepharonFornixTherapeutic useDiagnostico penfigoide ocular cicatricialGeneral MedicineComplement C3medicine.diseaseDermatologyeye diseasesAgentes inmunosupresoresmedicine.anatomical_structureMethotrexateImmunoglobulin MEtiologiaImmunoglobulin GEtiologyImmunohistochemistryMethotrexateComplicaciones cicatrizFemalesense organsPenfigoide ocular cicatricialmedicine.symptomImmunosuppressive agentsbusinessConjunctivaImmunosuppressive Agentsmedicine.drug

description

Abstract Clinical case A 73 year-old woman presented with a history of non-specific symptoms and photophobia in both eyes of 1 year progression. The examination revealed a bilateral symblepharon and fornix shortening. Immunohistochemical analysis confirmed the presence of linear deposits of IgG, IgM and C3 along the conjunctival basement membrane. With the diagnosis of ocular cicatricial pemphigoid, systemic treatment with subcutaneous methotrexate was prescribed. Discussion We consider such treatment a very effective initial immunosuppressive alternative in patients with moderate conjunctival inflammation and in cases of rapid progression.

yearjournalcountryeditionlanguage
2013-09-14Archivos de la Sociedad Espanola de Oftalmologia
10.1016/j.oftal.2013.10.009https://pubmed.ncbi.nlm.nih.gov/24359845